People in the denominator are matched for age (to match to ‘age at diagnosis’ for people in the cancer cohort), sex and calendar year.
Analysis will be undertaken using the ‘cohort’ method of calculation. See AIHW 2008, Cancer survival and prevalence in Australia: Cancers diagnosed from 1982 to 2004, Cancer Series no. 42. Cat. no. CAN 38.
100 x (Numerator ÷ Denominator)
Proportion of people diagnosed with cancer who survived for five years after diagnosis
Numerator data elements:
Proportion of similar people in the general population who survived for the same period. 'Similar people' are matched to the cancer cohort in the numerator for age, sex and calendar year.
Denominator data elements:
Disaggregation data elements:
Specified disaggregation: Nationally: sex, remoteness area, SEIFA of residence at diagnosis.
Available disaggregation: Nationally: sex, remoteness area, SEIFA of residence at diagnosis.
Data are currently produced irregularly, according to funded adhoc requests.
Most recent data available for 2010 CRC baseline report: Survival proportions for cancer diagnosed in 1998-2004.
A National Minimum Data Set (NMDS) for Cancer Registry data is under development.
Indigenous identification data are not considered to be adequate enough to support analysis or generation of life tables and are therefore in need of improvement to allow reporting by Indigenous status in future.
The indicator as currently specified is not age adjusted which limits comparability across groups and over time. The period method of calculating relative survival may be more appropriate for long-term trend analysis, but would require some developmental work.
Cancer ‘staging’ and ‘treatment’ data are not currently available nationally and cancer survival analysis would benefit greatly from this additional information.
Other issues caveats:
Disaggregation by state/territory is not available for the 2010 CRC report. It requires calculation against jurisdictional life tables and approval from cancer registries.
Survival rates vary for different types of cancer.